tetano
Editor, Senior Moderator
Res Vet Sci
. 2022 Feb 8;145:46-49.
doi: 10.1016/j.rvsc.2022.02.003. Online ahead of print.
A SARS-CoV-2 nanobody that can bind to the RBD region may be used for treatment in COVID-19 in animals
Peng Wu[SUP] 1 [/SUP], Qin Yang[SUP] 2 [/SUP], Xiaoli Zhao[SUP] 2 [/SUP], Qingqing Liu[SUP] 2 [/SUP], Jing Xi[SUP] 2 [/SUP], Fan Zhang[SUP] 2 [/SUP], Jinke He[SUP] 2 [/SUP], Hang Yang[SUP] 2 [/SUP], Chao Zhang[SUP] 2 [/SUP], Zhongchen Ma[SUP] 2 [/SUP], Xiaoyu Deng[SUP] 2 [/SUP], Yong Wang[SUP] 2 [/SUP], Chuangfu Chen[SUP] 3 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19) caused by an infectious virus, severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), poses a threat to the world. The suitable treatments must be identified for this disease in animals. Nanobody have therapeutic potential in the COVID-19. In this study, SARS-CoV-2 Spike RBD protein was used to make the nanobody. Nanobodies binding to the SARS-CoV-2 Spike RBD protein was obtained. Interestingly, the nanobody could bind to SARS-CoV-2 Spike S protein and RBD protein at the same time. Nanobodies were validated with a neutralizing antibody detection kit. The use of pseudoviruses confirmed that nanobodies could prevent pseudoviruses from infecting cells. We believe the nanobody are very valuable and could be used in the treatment of COVID-19. SARS-CoV-2 nanobodies can be rapidly mass-produced from microorganisms to block SARS-CoV-2 infection in vitro and in vivo with preventive and therapeutic effects.
Keywords: Coronavirus disease 2019; Nanobody; RBD protein; S protein; SARS-CoV-2.
. 2022 Feb 8;145:46-49.
doi: 10.1016/j.rvsc.2022.02.003. Online ahead of print.
A SARS-CoV-2 nanobody that can bind to the RBD region may be used for treatment in COVID-19 in animals
Peng Wu[SUP] 1 [/SUP], Qin Yang[SUP] 2 [/SUP], Xiaoli Zhao[SUP] 2 [/SUP], Qingqing Liu[SUP] 2 [/SUP], Jing Xi[SUP] 2 [/SUP], Fan Zhang[SUP] 2 [/SUP], Jinke He[SUP] 2 [/SUP], Hang Yang[SUP] 2 [/SUP], Chao Zhang[SUP] 2 [/SUP], Zhongchen Ma[SUP] 2 [/SUP], Xiaoyu Deng[SUP] 2 [/SUP], Yong Wang[SUP] 2 [/SUP], Chuangfu Chen[SUP] 3 [/SUP]
Affiliations
- PMID: 35152188
- DOI: 10.1016/j.rvsc.2022.02.003
Abstract
Coronavirus disease 2019 (COVID-19) caused by an infectious virus, severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), poses a threat to the world. The suitable treatments must be identified for this disease in animals. Nanobody have therapeutic potential in the COVID-19. In this study, SARS-CoV-2 Spike RBD protein was used to make the nanobody. Nanobodies binding to the SARS-CoV-2 Spike RBD protein was obtained. Interestingly, the nanobody could bind to SARS-CoV-2 Spike S protein and RBD protein at the same time. Nanobodies were validated with a neutralizing antibody detection kit. The use of pseudoviruses confirmed that nanobodies could prevent pseudoviruses from infecting cells. We believe the nanobody are very valuable and could be used in the treatment of COVID-19. SARS-CoV-2 nanobodies can be rapidly mass-produced from microorganisms to block SARS-CoV-2 infection in vitro and in vivo with preventive and therapeutic effects.
Keywords: Coronavirus disease 2019; Nanobody; RBD protein; S protein; SARS-CoV-2.